C Ray Therapeutics, a China-based radiopharmaceutical CRDMO, used the week to underscore its expanding role across the radioligand therapy value chain. The company announced a strategic partnership with SHINE Technologies, securing long-term, GMP-grade, no-carrier-added lutetium-177 from SHINE’s Cassiopeia facility for exclusive distribution in mainland China, subject to existing SHINE relationships.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
C Ray plans to channel this Lu-177 supply to Chinese radiopharmaceutical developers, biotech firms, and hospitals, leveraging its 28,000-square-meter Chengdu site for conjugation, fill-and-finish, and quality control. By combining Lu-177 access with its existing Actinium-225 capabilities, the company is positioning itself as a core infrastructure player for targeted radiopharmaceutical therapies and radioligand programs from preclinical through Phase III.
The company also highlighted broader supply-chain themes, emphasizing the industry shift toward high-purity, scalable production of Lu-177 and Ac-225 and the competitive advantage of n.c.a. isotopes over carrier-added alternatives. C Ray framed secure, reliable isotope sourcing as increasingly critical for Asian radiopharma pipelines, with supply consistency becoming a regulatory and commercial differentiator as programs advance.
On the technology and ecosystem front, C Ray spotlighted automation partnerships with TRUKING and STÄUBLI to deploy Stericlean robotic systems for GMP-compliant aseptic manufacturing. It also continued to champion localized alpha therapies using Ra-224 for peritoneal metastases, while pointing to Pb-212 supply challenges and emerging models such as Thor Medical’s thorium-based production to address logistics and half-life constraints.
C Ray’s co-organizing role at the International RDC Sub-Forum at XDC 2026 in Chengdu further reinforced its thought-leadership ambitions. The company is using the conference to showcase advances in ligand design, including ultra-small protein scaffolds from partners such as Navigo Proteins, aimed at better matching pharmacokinetics with short half-life isotopes like Pb-212 and Ac-225.
Taken together, the week’s announcements and communications suggest C Ray Therapeutics is consolidating its position as a key platform partner in nuclear medicine, integrating isotope supply, advanced manufacturing, and next-generation RLT design. These developments may enhance its attractiveness as a collaborator for domestic and international radiopharma players and support its long-term role in China’s fast-growing targeted oncology market.